2026 ICD-10-CM Diagnosis Code T43.625SAdverse effect of amphetamines, sequela
T43.625S is a billable ICD-10-CM diagnosis code for adverse effect of amphetamines, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as amphetamine group adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Mental and substance use disorders; sequela; and Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T43.625S.
Present on Admission (POA)Billing
T43.625S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Amphetamine group adverse reaction
- Dexamphetamine adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified (T43). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Dextroamphetamine
the d-form of amphetamine. it is a central nervous system stimulant and a sympathomimetic. it has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. it is also a drug of abuse and a psychotomimetic.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Amfetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Amfetaminil | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Amphetamine NEC | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Benzedrine (amphetamine) | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Dexamfetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Dexamphetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Dexedrine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Dextroamphetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Methylenedioxyamphetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
| Tenamfetamine | T43.621 | T43.622 | T43.623 | T43.624 | T43.625 | T43.626 |
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T43.625S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T43.625SOverview
Is T43.625S (Adverse effect of amphetamines) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of amphetamines, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T43.625S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of amphetamines itself has resolved, not the original event.
What MS-DRG does T43.625S group to?
On inpatient claims, adverse effect of amphetamines, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T43.625S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of amphetamines, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T43.625S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of amphetamines, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
